NCI The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades agoLowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” February 13, 2026Vol.52 No.06By Jacquelyn Cobb
Regulatory News CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot February 13, 2026Vol.52 No.06By Claire Marie Porter
NCI NCAB ad hoc group approves seven new, reissue concepts February 13, 2026Vol.52 No.06By Sara Willa Ernst
Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
Cancer Policy Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test February 13, 2026Vol.52 No.06By Jacquelyn Cobb and Sara Willa Ernst
Cancer Policy FDA approves labeling changes to menopausal hormone therapy products February 13, 2026Vol.52 No.06By Claire Marie Porter
Cancer Policy HHS withdraws 340B drug rebate pilot program February 13, 2026Vol.52 No.06By Sara Willa Ernst
In Brief David Gius named director of University of Cincinnati Cancer Center February 13, 2026Vol.52 No.06
In Brief Team USA’s Julie Letai competes in Milan Olympics speed skating event February 13, 2026Vol.52 No.06
In Brief “The Journey to End Cancer: From Cause to Cure” exhibit launches national tour, with MD Anderson as presenting sponsor February 13, 2026Vol.52 No.06
